Table 3

Select DRG gene expression after PEGPH20 administration (1–7 d)

GeneD1D3D5D7
TrkA21.9 ± 13.570.2 ± 8.0−60.7 ± 13.4*−52.2 ± 30.3
P2X349.8 ± 13.1458.3 ± 13.8***114.8 ± 29.2459.6 ± 25.9**
P2X5−4.4 ± 10.2−63.9 ± 39.1−37.0 ± 38.9−62.8 ± 15.9
TRPV19.3 ± 15.258.6 ± 9.0−66.3 ± 20.1−63.4 ± 49.4
TRPA1−23.8 ± 12.6−13.66 ± 113.0358.3 ± 28.6−32.99 ± 37.53
ASIC30.8 ± 7.27.5 ± 5.0−82.77 ± 110.1−76.33 ± 61.62
GFRα1−2.8 ± 7.3−81.8 ± 12.1**−93.1 ± 26.8***−97.6 ± 56.1***
GFRα230.3 ± 18.8−44.8 ± 95.9−55.9 ± 41.4−69.2 ± 29.4
GFRα3−7.6 ± 5.5−60.5 ± 120.6−18.5 ± 37.31−37.8 ± 14.72
IL1r1−17.9 ± 11.9−90.1 ± 85.3*−83.3 ± 28.5−89.1 ± 7.9*
  • Values indicate % change versus vehicle-treated controls. Mean ± SEM n = 4 per group per time point. One-way ANOVA (TrkA F(4,14) = 10.57, p = 0.0004; P2X3 F(4,14) = 17.27, p < 0.0001; GFRα1 F(4,13) = 29.57, p < 0.0001; LI1r1 F(4,12) = 8.272, p = 0.0019) with Bonferroni post hoc. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle-treated controls. GAPDH CT (mean ± SEM) CTRL: 20.97 ± 0.26; D1 19.651 ± 0.07; D3 20.295 ± 0.45 D5 21.2 ± 0.39 D7 22.32 ± 0.82. No significant differences were detected between the CTRL or treatment groups (one-way ANOVA F(4,14) = 3.8, p = 0.026).